DESHLER, Ohio, Aug 3 (Bernama-BUSINESS WIRE) -- Graminex® LLC is pleased to announce the US Patent Office has rejected Serelys’ patents for use of its pollen extracts in treating women's PMS and menopausal symptoms.
In parallel reexamination proceedings against US Patents 6,569,471 and 6,669,967, the US Patent Office recently rejected all claims of both patents. Based on overwhelming evidence submitted, the Office found the claimed solvent-extracted GC FEM and PI 82 pollen extracts, for use in treating PMS and menopausal symptoms in women, to be unpatentable. The Final Rejections are available for download at USPTO Public PAIR (https://portal.uspto.gov/pair/PublicPair) under reexamination serial numbers 90/014,026 and 90/014,027, where a full public record of the evidence and detailed explanation for the loss of patent coverage can be found.
In parallel reexamination proceedings against US Patents 6,569,471 and 6,669,967, the US Patent Office recently rejected all claims of both patents. Based on overwhelming evidence submitted, the Office found the claimed solvent-extracted GC FEM and PI 82 pollen extracts, for use in treating PMS and menopausal symptoms in women, to be unpatentable. The Final Rejections are available for download at USPTO Public PAIR (https://portal.uspto.gov/pair/PublicPair) under reexamination serial numbers 90/014,026 and 90/014,027, where a full public record of the evidence and detailed explanation for the loss of patent coverage can be found.
No comments:
Post a Comment